NanoVation Therapeutics

Recent Finacing

Equity

Recent Raise

Undisclosed

NanoVation Therapeutics develops long‑circulating lipid nanoparticle (lcLNP) delivery platforms for functional nucleic acid targeting to extrahepatic cell types and partners with pharma/biotech to advance genetic medicines.

Founded 2020

British Columbia, Canada

11-50

Private

nanovationtx.com

Highlights

Focus Areas

Biotechnology

Nanotechnology

Therapeutics

Recent Investors

Financials

1

Funding round

1

Investor

Team

Upgrade to view the team

See the team members at NanoVation Therapeutics.